Reported Q: Q2 2025 Rev YoY: +89,539.3% EPS YoY: -1,356.0% Move: -1.64%
InMed Pharmaceuticals Inc
IN.TO
$4.19 -1.64%
Exchange TSX Sector Healthcare Industry Biotechnology
Q2 2025
Published: Feb 12, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for IN.TO

Reported

Report Date

Feb 12, 2025

Quarter Q2 2025

Revenue

1.11B

YoY: +89,539.3%

EPS

-3.64

YoY: -1,356.0%

Market Move

-1.64%

Previous quarter: Q1 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $1.11B up 89% year-over-year
  • EPS of $-3.64 decreased by 1% from previous year
  • Gross margin of 41.5%
  • Net income of -2.58B
  • "N/A" - N/A
IN.TO
Company IN.TO

Swipe to view all report sections

Executive Summary

InMed Pharmaceuticals reported QQ2 2025 results with revenue of USD 1.1117 billion and a gross margin of approximately 41.5%, underscored by substantial operating expenses driven by R&D and G&A. The company posted a net loss of USD 2.575 billion and an EPS of −$3.64 for the quarter, reflecting the ongoing burn typical of early-stage biotechnology pipelines and the timing of milestone-driven costs. Despite the heavy negative bottom-line print, the balance sheet suggests meaningful liquidity with cash and equivalents reported around USD 3.42 billion and modest total debt, implying a potential runway to advance core programs (INM755, INM088, INM405) through pivotal trial milestones and possible collaborations. However, meaningful questions remain around near-term profitability, the cadence of clinical readouts, and the requirement for additional fundraising given the scale of R&D and G&A expenditures.

Key Performance Indicators

Revenue
Increasing
1.11B
QoQ: 87 807.13% | YoY: 89 539.33%
Gross Profit
Increasing
460.89M
41.46% margin
QoQ: 93 309.38% | YoY: 142 088.92%
Operating Income
Decreasing
-2.15B
QoQ: N/A | YoY: -30.52%
Net Income
Decreasing
-2.58B
QoQ: -53.47% | YoY: -174 101.74%
EPS
Decreasing
-3.64
QoQ: -34.32% | YoY: -1 356.00%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 1,261.58 -1.94 +107.0% View
Q2 2025 1,111.71 -3.64 +89.0% View
Q1 2025 1.26 -2.71 -45.3% View
Q4 2024 1.28 -0.22 -24.1% View
Q3 2024 1.17 -0.24 +13.4% View